Dosage and administration of osimertinib/osimertinib

Osimertinib (Osimertinib) is an oral targeted therapy drug, mainly used to treat EGFR (epidermal growth factor receptor) gene mutation-positive advanced non-small cell lung cancer (NSCLC). The correct dosage and method of administration are critical to patient outcomes. The following is a detailed introduction to the dosage and administration methods of osimertinib/osimertinib:

1.Dosage:Osimertinib/The recommended dose of Osimertinib is 80 mg (mg) taken orally once daily. Dosage selection is usually determined based on the patient's specific circumstances, including factors such as age, body mass index (BMI), liver function, and kidney function. Before starting treatment, the doctor will determine the most appropriate dose based on the patient's disease state and individual characteristics.

2.Dosage method:Osimertinib/Osimertinib is usually taken on an empty stomach or 2 hours after a meal to ensure the best absorption of the drug. Patients should swallow the tablets whole and drink them with a sufficient amount of water (approximately 200 milliliters). It is not recommended to chew Osimertinib tablets or break them in half, as this may affect the release rate and absorption of the drug.

3.Dose adjustment: During treatment, the doctor will adjust the dose according to the patient's disease status and drug tolerance. For patients who experience serious adverse reactions or specific side effects, a dose reduction or treatment suspension may be necessary to reduce discomfort and protect the patient's health.

4.Usage in special populations: For special populations, such as elderly patients, patients with impaired liver function, patients with impaired renal function, and pregnant women, caution is requiredOsimertinib/Osimertinib and adjust the dose on a case-by-case basis. For patients with impaired hepatic function, a dose reduction may be necessary; for patients with impaired renal function, dose adjustment is generally not required; pregnant women should avoid exposure to osimertinib/osimertinib due to the potential for harm to the fetus.

5.Follow the doctor's advice and conduct regular follow-up visits: Patients should strictly abide by the doctor's recommendations and instructions during medication, conduct regular follow-up visits, and report any symptoms of discomfort in a timely manner to ensure the safety and effectiveness of treatment. Doctors will make adjustments based on the patient's disease status and drug tolerance, and provide patients with necessary support and guidance.

6.Interactions: During medication, patients should avoid interactions with other drugs, especially CYP3A4 and P-gp span> inhibitors and inducers, so as not to affect the pharmacokinetics of osimertinib/osimertinib.

In summary, the correct dosage and method of Osimertinib/Osimertinib are crucial to the patient's therapeutic effect. Patients should use osimertinib correctly under the guidance of a doctor, have regular follow-up visits, and report any adverse reactions in a timely manner to ensure the smooth progress of treatment, improve treatment effects, and improve the quality of life.